H.C. Wainwright raised the firm’s price target on Regenxbio (RGNX) to $40 from $39 and keeps a Buy rating on the shares following the Q3 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX: